dendritic cells

Cell therapyexperimental

A dendritic cell (DC) is an antigen-presenting cell of the mammalian immune system. A DC's main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and adaptive immune systems. — Wikipedia

Clinical trial activity

52 trials · 65 clinical orgs · 0 marketing orgs

Phase 1
31
Phase 2
36
Phase 3
1
Phase 4
0

Earliest trial started Jan 1, 2004 (NCT00185874)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Unspecified targetImmunity, active

    immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dendritic cell
  • dendritic cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06172634Phase 1/Phase 2 (Phase 2)Mar 1, 2024Soonchunhyang University
NCT04212377Phase 2Apr 8, 2019Katholieke Universiteit Leuven, Radboud University
NCT03067493Phase 2Apr 1, 2017Guangzhou Medical University, Sun Yat-Sen University
NCT03035331Phase 1/Phase 2 (Phase 2)Mar 27, 2017Mayo Clinic, National Cancer Institute (NCI)
NCT02993315Phase 3Oct 1, 2016Radboud University, ZonMw: The Netherlands Organisation for Health Research and Development, Zorginstituut Nederland
NCT02873416Phase 1/Phase 2 (Phase 2)Aug 1, 2016Ningbo Cancer Hospital, Ningbo No. 5 Hospital, Shanghai Cell Therapy Research Institute
NCT02873442Phase 1/Phase 2 (Phase 2)Aug 1, 2016Ningbo Cancer Hospital, Ningbo No. 5 Hospital, Shanghai Cell Therapy Research Institute
NCT02862613Phase 1/Phase 2 (Phase 2)Aug 1, 2016Fudan University
NCT02873520Phase 1/Phase 2 (Phase 2)Aug 1, 2016Ningbo Cancer Hospital, Ningbo No. 5 Hospital, Shanghai Cell Therapy Research Institute
NCT02862561Phase 1/Phase 2 (Phase 2)Aug 1, 2016Fudan University
NCT02862587Phase 1/Phase 2 (Phase 2)Aug 1, 2016Fudan University
NCT02886897Phase 1/Phase 2 (Phase 2)Jul 1, 2016Sun Yat-Sen University
NCT02771301N/AFeb 1, 2016Capital Medical University, Hebei University
NCT02669719Phase 2Jan 1, 2016Accord Research, Jiao Tong University
NCT02638857Phase 1/Phase 2 (Phase 2)Sep 1, 2015Eastern Hepatobiliary Surgery Hospital, People's Liberation Army of China
NCT02366728Phase 2Sep 1, 2015Duke University
NCT02432378Phase 1/Phase 2 (Phase 2)Jul 1, 2015Hemispherx Biopharma, National Cancer Institute (NCI), University of Pittsburgh
NCT02961829N/AJul 1, 2015Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo, University of Sao Paulo, ViiV Healthcare
NCT02529579Phase 1/Phase 2 (Phase 2)Jun 1, 2015Changhai Hospital, ImmunoGenes, People's Liberation Army of China
NCT02423928Phase 1May 1, 2015Alden Cancer Therapy II, Bergen Health, University of Bergen, University of Oslo
Showing 20 of 52 trials
Page 1 / 3

Organizations

Research & Development (65)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government8022006
University of PittsburghAcademic/Hospital5522006
Radboud UniversityAcademic/Hospital4422004
Fudan UniversityAcademic/Hospital3312016
Guangxi Medical UniversityAcademic/Hospital3312013
Ningbo Cancer HospitalAcademic/Hospital3312016
Ningbo No. 5 HospitalAcademic/Hospital3012016
Shanghai Cell Therapy Research InstituteAcademic/Hospital3012016
Dartmouth UniversityAcademic/Hospital2212006
People's Liberation Army of ChinaGovernment2112015
Stanford UniversityAcademic/Hospital2212004
Sun Yat-Sen UniversityAcademic/Hospital2212016
University of California, Los AngelesAcademic/Hospital2222012
Accord ResearchFor profit1012016
Alden Cancer Therapy IIAcademic/Hospital1112015
Bergen HealthAcademic/Hospital1012015
Cancer Research InstituteAcademic/Hospital1012005
Cancer Treatment Research FoundationAcademic/Hospital1012006
Capital Medical UniversityAcademic/Hospital1012016
Changhai HospitalAcademic/Hospital1112015
65 organizations
Page 1 / 4